SITE014-0113

SITE014 (NLD) › SITE014-0113

SITE014-0113

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-01-12

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 226); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 110); relationship: RELATED

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-03 (study day 103); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 100); relationship: NOT RELATED

moderate assessed

Grade 2 Thrombocytopenia — outcome: UNKNOWN; onset 2022-10-29 (study day 98); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.